Paris

• A first-in-human study to determine a safe dose of the drug TD001 to treat patients with metastatic prostate cancer that expresses the PSMA … Recruiting
  2025-523273-41-00 7 2026-01-30 Metastatic castration-resistant prostate cancer
• NUCastle - Nintedanib treatment in Unicentric Castleman disease Recruiting
  2023-510253-42-00 4 2026-01-28 Adult patients aged 18 and over with unicentric hyalino-vascular Castl
• CombiChronoS - Effectiveness of a Combination of Chronotherapeutics for the Treatment of Major Depressive Episode (MDE) with Insomnia: A Mul … Recruiting
  2024-516371-32-00 5 2026-01-28 insomnia
• Long-Term Extension Study of Vosoritide to Treat Children with Hypochondroplasia Recruiting
  2024-517238-16-00 5 2026-01-28 Hypochondroplasia
• Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af … Recruiting
  2025-522400-24-00 10 2026-01-27 Metastatic urothelial cancer
• FT819 in B-cell Mediated Autoimmune Diseases Recruiting
  2024-517397-25-00 1 2026-01-26 B-cell Mediated Autoimmune Diseases
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Metastatic Clear Cell Renal Cell Carcinoma
• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o … Recruiting
  2024-515658-26-00 5 2026-01-21 Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
• A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting
  2025-521917-24-00 5 2026-01-21 Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
• FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev … Recruiting
  2023-505781-28-00 4 2026-01-20 Patients with Waldenstrom macroglobulinemia and have received at least
• A dose-ranging randomized, open-label study evaluating the effect of bilateral intravitreal injection of GS010 at two dose levels on visual … Recruiting
  2025-523339-20-00 4 2026-01-20 Leber Hereditary Optic Neuropathy due to mutations in the mitochondria
• A study to learn about how well BAY 3401016 works in adults with Alport syndrome Recruiting
  2024-516471-33-00 4 2026-01-19 Alport Syndrome
• ​​Vorasidenib for the treatment of IDH-mutant astrocytoma after standard chemoradiotherapy Recruiting
  2024-519404-27-00 5 2026-01-16 ​​IDH-mutant grade 2 or 3 astrocytoma​
• Efficacy of intravesical oxybutynin in children with neurogenic bladder dysfunction: A randomized, prospective controlled multi-center trial … Recruiting
  2022-501902-36-00 5 2026-01-15 spina bifida
• An open-label phase II trial to evaluate the clinical efficacy, safety and tolerability of MAS825 in pediatric and adult participants with S … Recruiting
  2024-520208-25-00 4 2026-01-15 Still’s disease
• A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting
  2025-522683-32-00 5 2026-01-15 Early-Stage Parkinson’s Disease (PD)
• LA-HCM : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients with Abnormal Left Atrial Strain : A Randomized M … Recruiting
  2024-511084-28-00 11 2026-01-12 Hypertrophic Cardiomyopathie
• NEOREM/NEO-1 - NEOREM: Neo-adjuvant Immunotherapy Master Trial for Localized Cancers / NEO-1: Neo-adjuvant immunotherapy in patients with l … Recruiting
  2025-522127-95-00 4 2026-01-12 NEOREM: Localized solid malignancies that are eligible to receive neo-
• ANACOMP. A RANDOMIZED PHASE III MULTICENTER TRIAL COMPARING THE EFFICACY AND SAFETY OF ANAKINRA VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) RET … Recruiting
  2024-516244-25-00 5 2026-01-06 Kawasaki disease
• Early detection of triple negative breast cancer relapse (CUPCAKE) Recruiting
  2022-501562-22-01 4 2026-01-05 Triple-negative breast cancer (TNBC) patients at high risk of relapse
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran … Recruiting
  2024-511437-35-00 10 2026-01-05 Patients aged 18-65 years old with newly diagnosed previously untreate
• A study of belumosudil in children with chronic graft versus host disease (schoolROCK). Recruiting
  2024-511508-18-00 9 2026-01-05 Chronic graft versus host disease.
• Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Recruiting
  2024-513330-38-00 4 2026-01-02 Healthy volunteers : Healthy adults with no history of gastrointestin
• A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in P … Recruiting
  2024-515172-12-00 4 2025-12-23 Epidermolysis Bullosa

Showing 529–552 of 2,286 trials